Clinical effect and metabolism of S-sulfonated immunoglobulin in 7 patients with congenital humoral immunodeficiency.
7 patients with primary humoral immunodeficiency were given an S-sulfonated IgG preparation, 100 mg/kg i.v. at intervals of 3--4 weeks, for treatment of, or prophylaxis  against, infection. The clinical effects and metabolism of S-sulfonated IgG were studied. No side reactions attributable to S-sulfonated IgG occurred in any of the patients. The S-sulfonated IgG was completely transformed into intact IgG within 24 h after administration, and had a mean half-life of 21 days, comparable to that of intact IgG. Complete restoration of IgG Fc fragment activity occurred within 24 h following injection, as assessed by reversed passive cutaneous anaphylaxis.
D000818:Animals; D001424:Bacterial Infections / Q000517:prevention & control / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D006168:Guinea Pigs; D006207:Half-Life; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000378:metabolism*; D007153:Immunologic Deficiency Syndromes / Q000151:congenital / Q000378:metabolism*; D007275:Injections, Intravenous; D008297:Male; D010323:Passive Cutaneous Anaphylaxis; D013451:Sulfonic Acids / Q000378:metabolism
C021306:IgG, sulfonated; D007074:Immunoglobulin G; D013451:Sulfonic Acids